Bray F, Laversanne M, Weiderpass E, Soerjomataram I. The ever-increasing importance of cancer as a leading cause of premature death worldwide. Cancer. 2021;127:3029–30. https://doi.org/10.1002/cncr.33587.

Article  PubMed  Google Scholar 

Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17–48. https://doi.org/10.3322/caac.21763.

Article  PubMed  Google Scholar 

Kashyap D, Pal D, Sharma R, Garg VK, Goel N, Koundal D, Zaguia A, Koundal S, Belay A. Global increase in Breast Cancer incidence: risk factors and preventive measures. Biomed Res Int. 2022;2022:9605439. https://doi.org/10.1155/2022/9605439.

Article  PubMed  PubMed Central  Google Scholar 

Azimnasab-Sorkhabi P, Soltani-Asl M, Kfoury JR Jr., Algenstaedt P, Mehmetzade HF, Hashemi Aghdam Y. The impact of leptin and its receptor polymorphisms on type 1 Diabetes in a population of northwest Iran. Ann Hum Biol. 2022;49:317–22. https://doi.org/10.1080/03014460.2022.2134453.

Article  PubMed  Google Scholar 

Soltani Asl M, Azimnasab-Sorkhabi P, Abolfathi AA, Hashemi Aghdam Y. Identification of nucleotide polymorphism within the NeuroD1 candidate gene and its association with type 1 Diabetes susceptibility in Iranian people by polymerase chain reaction-restriction fragment length polymorphism. J Pediatr Endocrinol Metab. 2020;33:1293–7. https://doi.org/10.1515/jpem-2019-0441.

Article  PubMed  Google Scholar 

Duffy MJ, Synnott NC, Crown J. Mutant p53 as a target for cancer treatment. Eur J Cancer. 2017;83:258–65. https://doi.org/10.1016/j.ejca.2017.06.023.

Article  PubMed  Google Scholar 

Di Gregorio J, Petricca S, Iorio R, Toniato E, Flati V. Mitochondrial and metabolic alterations in cancer cells. Eur J Cell Biol. 2022;101:151225. https://doi.org/10.1016/j.ejcb.2022.151225.

Article  PubMed  Google Scholar 

Azimnasab-Sorkhabi P, Soltani-Asl M, Kfoury Junior JR. Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) as an undetermined tool in Tumor cells. Hum Cell. 2023;36:1225–32. https://doi.org/10.1007/s13577-023-00893-8.

Article  PubMed  Google Scholar 

Azimnasab-Sorkhabi P, Soltani-Asl M, Yoshinaga TT, Massoco CO, Kfoury Junior JR. IDO blockade negatively regulates the CTLA-4 signaling in Breast cancer cells. Immunol Res. 2023. https://doi.org/10.1007/s12026-023-09378-0.

Article  PubMed  Google Scholar 

Ye Z, Yue L, Shi J, Shao M, Wu T. Role of IDO and TDO in cancers and related Diseases and the therapeutic implications. J Cancer. 2019;10:2771–82. https://doi.org/10.7150/jca.31727.

Article  PubMed  PubMed Central  Google Scholar 

van Baren N, Van den Eynde BJ. Tryptophan-degrading enzymes in tumoral immune resistance. Front Immunol. 2015;6:34. https://doi.org/10.3389/fimmu.2015.00034.

Article  PubMed  PubMed Central  Google Scholar 

Azimnasab-Sorkhabi P, Soltani-Asl M, Yoshinaga TT, Zaidan Dagli ML, Massoco CO, Kfoury Junior JR. Indoleamine-2,3 dioxygenase: a fate-changer of the Tumor microenvironment. Mol Biol Rep. 2023;50:6133–45. https://doi.org/10.1007/s11033-023-08469-3.

Article  PubMed  Google Scholar 

Trikha P, Lee DA. The role of AhR in transcriptional regulation of immune cell development and function. Biochim Biophys Acta Rev Cancer. 2020;1873:188335. https://doi.org/10.1016/j.bbcan.2019.188335.

Article  PubMed  Google Scholar 

Elson DJ, Kolluri SK. Tumor-suppressive functions of the Aryl Hydrocarbon receptor (AhR) and AhR as a therapeutic target in Cancer. Biology (Basel). 2023;12. https://doi.org/10.3390/biology12040526.

Granados JC, Falah K, Koo I, Morgan EW, Perdew GH, Patterson AD, Jamshidi N, Nigam SK. AHR is a master regulator of diverse pathways in endogenous metabolism. Sci Rep. 2022;12:16625. https://doi.org/10.1038/s41598-022-20572-2.

Article  PubMed  PubMed Central  Google Scholar 

Larigot L, Juricek L, Dairou J, Coumoul X. AhR signaling pathways and regulatory functions. Biochim Open. 2018;7:1–9. https://doi.org/10.1016/j.biopen.2018.05.001.

Article  PubMed  PubMed Central  Google Scholar 

Patel RD, Murray IA, Flaveny CA, Kusnadi A, Perdew GH. Ah receptor represses acute-phase response gene expression without binding to its cognate response element. Lab Invest. 2009;89:695–707. https://doi.org/10.1038/labinvest.2009.24.

Article  PubMed  PubMed Central  Google Scholar 

Xue P, Fu J, Zhou Y. The Aryl Hydrocarbon receptor and Tumor immunity. Front Immunol. 2018;9:286. https://doi.org/10.3389/fimmu.2018.00286.

Article  PubMed  PubMed Central  Google Scholar 

Vacher S, Castagnet P, Chemlali W, Lallemand F, Meseure D, Pocard M, Bieche I, Perrot-Applanat M. High AHR expression in breast tumors correlates with expression of genes from several signaling pathways namely inflammation and endogenous tryptophan metabolism. PLoS ONE. 2018;13:e0190619. https://doi.org/10.1371/journal.pone.0190619.

Article  PubMed  PubMed Central  Google Scholar 

Murray IA, Patterson AD, Perdew GH. Aryl hydrocarbon receptor ligands in cancer: friend and foe. Nat Rev Cancer. 2014;14:801–14. https://doi.org/10.1038/nrc3846.

Article  PubMed  PubMed Central  Google Scholar 

Opitz CA, Somarribas Patterson LF, Mohapatra SR, Dewi DL, Sadik A, Platten M, Trump S. The therapeutic potential of targeting tryptophan catabolism in cancer. Br J Cancer. 2020;122:30–44. https://doi.org/10.1038/s41416-019-0664-6.

Article  PubMed  Google Scholar 

Tomblin JK, Arthur S, Primerano DA, Chaudhry AR, Fan J, Denvir J, Salisbury TB. Aryl hydrocarbon receptor (AHR) regulation of L-Type amino acid transporter 1 (LAT-1) expression in MCF-7 and MDA-MB-231 Breast cancer cells. Biochem Pharmacol. 2016;106:94–103. https://doi.org/10.1016/j.bcp.2016.02.020.

Article  PubMed  PubMed Central  Google Scholar 

Takenaka MC, Gabriely G, Rothhammer V, Mascanfroni ID, Wheeler MA, Chao CC, Gutiérrez-Vázquez C, Kenison J, Tjon EC, Barroso A, Vandeventer T, de Lima KA, Rothweiler S, Mayo L, Ghannam S, Zandee S, Healy L, Sherr D, Farez MF, Prat A, Antel J, Reardon DA, Zhang H, Robson SC, Getz G, Weiner HL, Quintana FJ. Author correction: control of tumor-associated macrophages and T cells in glioblastoma via AHR and CD39. Nat Neurosci. 2019;22:1533. https://doi.org/10.1038/s41593-019-0446-8.

Article  PubMed  PubMed Central  Google Scholar 

Vogel CFA, Lazennec G, Kado SY, Dahlem C, He Y, Castaneda A, Ishihara Y, Vogeley C, Rossi A, Haarmann-Stemmann T, Jugan J, Mori H, Borowsky AD, La Merrill MA, Sweeney C. Targeting the Aryl hydrocarbon receptor signaling pathway in Breast Cancer Development. Front Immunol. 2021;12:625346. https://doi.org/10.3389/fimmu.2021.625346.

Article  PubMed  PubMed Central  Google Scholar 

Safe S, Zhang L. The role of the Aryl Hydrocarbon Receptor (AhR) and its ligands in Breast Cancer. Cancers (Basel). 2022;14. https://doi.org/10.3390/cancers14225574.

Shi D, Wu X, Jian Y, Wang J, Huang C, Mo S, Li Y, Li F, Zhang C, Zhang D, Zhang H, Huang H, Chen X, Wang YA, Lin C, Liu G, Song L, Liao W. USP14 promotes tryptophan metabolism and immune suppression by stabilizing IDO1 in Colorectal cancer. Nat Commun. 2022;13:5644. https://doi.org/10.1038/s41467-022-33285-x.

Article  PubMed  PubMed Central  Google Scholar 

Brandacher G, Perathoner A, Ladurner R, Schneeberger S, Obrist P, Winkler C, Werner ER, Werner-Felmayer G, Weiss HG, G√∂bel G, Margreiter R, K√∂nigsrainer A, Fuchs D, Amberger A. Prognostic value of indoleamine 2,3-dioxygenase expression in Colorectal cancer: effect on tumor-infiltrating T cells. Clin Cancer Res. 2006;12:1144–51. https://doi.org/10.1158/1078-0432.CCR-05-1966.

Article  PubMed  Google Scholar 

Thaker AI, Rao MS, Bishnupuri KS, Kerr TA, Foster L, Marinshaw JM, Newberry RD, Stenson WF, Ciorba MA. IDO1 metabolites activate β-catenin signaling to Promote Cancer cell proliferation and Colon tumorigenesis in mice. Gastroenterology. 2013;145:416–425e414. https://doi.org/10.1053/j.gastro.2013.05.002.

Article  PubMed  Google Scholar 

Opitz CA, Litzenburger UM, Sahm F, Ott M, Tritschler I, Trump S, Schumacher T, Jestaedt L, Schrenk D, Weller M, Jugold M, Guillemin GJ, Miller CL, Lutz C, Radlwimmer B, Lehmann I, von Deimling A, Wick W, Platten M. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature. 2011;478:197–203. https://doi.org/10.1038/nature10491.

Article  PubMed  Google Scholar 

Xue C, Li G, Zheng Q, Gu X, Shi Q, Su Y, Chu Q, Yuan X, Bao Z, Lu J, Li L. Tryptophan metabolism in health and Disease. Cell Metab. 2023;35:1304–26. https://doi.org/10.1016/j.cmet.2023.06.004.

Article  PubMed  Google Scholar 

Liu X, Zhou W, Zhang X, Ding Y, Du Q, Hu R. 1-L-MT, an IDO inhibitor, prevented colitis-associated cancer by inducing CDC20 inhibition-mediated mitotic death of colon cancer cells. Int J Cancer. 2018;143:1516–29. https://doi.org/10.1002/ijc.31417.

Article  PubMed  Google Scholar 

Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E, Prendergast GC. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med. 2005;11:312–9. https://doi.org/10.1038/nm1196.

Article  PubMed  Google Scholar 

Jiang X, Li X, Zheng S, Du G, Ma J, Zhang L, Wang H, Tian J. Comparison study of different indoleamine-2,3 dioxygenase inhibitors from the perspective of pharmacodynamic effects. Int J Immunopathol Pharmacol. 2020;34:2058738420950584. https://doi.org/10.1177/2058738420950584.

Article  PubMed  PubMed Central  Google Scholar 

Fujiwara Y, Kato S, Nesline MK, Conroy JM, DePietro P, Pabla S, Kurzrock R. Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy. Cancer Treat Rev. 2022;110:102461. https://doi.org/10.1016/j.ctrv.2022.102461.

Article  PubMed  Google Scholar 

Atene CG, Fiorcari S, Mesini N, Alboni S, Martinelli S, Maccaferri M, Leonardi G, Potenza L, Luppi M, Maffei R, Marasca R. Indoleamine 2, 3-Dioxygenase 1 Mediates Survival Signals in chronic lymphocytic Leukemia via Kynurenine/Aryl hydrocarbon receptor-mediated MCL1 modulation. Front Immunol. 2022;13. https://doi.org/10.3389/fimmu.2022.832263.

Zhu J, Luo L, Tian L, Yin S, Ma X, Cheng S, Tang W, Yu J, Ma W, Zhou X, Fan X, Yang X, Yan J, Xu X, Lv C, Liang H. Aryl Hydrocarbon receptor promotes IL-10 expression in inflammatory macrophages through Src-STAT3 signaling pathway. Front Immunol. 2018;9.